BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xenogen Corporation (XGEN) Announces 2005 Fourth Quarter And Full Year Financial Results Release Date And Conference Call


2/23/2006 11:57:33 AM

ALAMEDA, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Xenogen Corporation , maker of advanced imaging systems including instruments, biological solutions and software designed to accelerate drug discovery and development, today announced that it will release 2005 fourth quarter and full-year financial results after the close of market on Thursday, March 2, 2006. Xenogen's management will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

What:

Xenogen will release 2005 fourth quarter and full-year results, followed by a teleconference.

When:

Teleconference begins on Thursday, March 2nd at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Who:

David Carter, Chief Executive Officer and Chairman; Dr. Pamela Contag, President; William Albright, Chief Financial Officer.

How:

Dial 800-946-0706 (domestic) or 719-457-2638 (international) to listen to the call. A live webcast also will be made available at www.xenogen.com.

A phone replay will be available for 48 hours following the completion of the call by dialing 888-203-1112 (domestic) or 719-457-0820 (international), and entering in reservation code 5244395. The webcast will be archived and available on the Xenogen website for 14 days.

About Xenogen Corporation

Xenogen Corporation is a leading biotechnology company offering an integrated suite of biophotonic real-time in vivo imaging and genetic modification technologies that can help expedite drug discovery and development, and significantly reduce the cost and time to market for new therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and monitor biological processes within living mammals, at the molecular level, in real time. The technology provides higher quality in vivo data earlier in the drug discovery and development process. VivoVision(TM) Solutions improve discovery and pre-clinical research in multiple therapeutic areas. VivoVision(TM) Biosciences represents more than 15 years of experience in the creation and characterization of animal models, including genetic modifications, comprehensive phenotyping, compound profiling and custom design and production of light producing cells, microorganisms and animals.

More information is available at www.xenogen.com.

NOTE: Xenogen(R), Living Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.

Xenogen Corporation

CONTACT: William A. Albright, Chief Financial Officer of XenogenCorporation, +1-510-291-6104; or investors, Jordan Goldstein of FinancialDynamics, +1-415-439-4500, for Xenogen Corporation; or media, Kelly O'Brienof Manning Selvage & Lee, +1-415-364-3840, for Xenogen Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES